1-3 of 3
Matthew J. Wong
Close
Sort by
Journal Articles

SGX70393 Inhibits Bcr-Abl T315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.

Thomas O’Hare, Christopher A. Eide, Jeffrey W. Tyner, Amie S. Corbin, Matthew J. Wong, Sean Buchanan, Kevin Holme, Katayoun A. Jessen, Crystal Tang, Hal A. Lewis, Richard D. Romero, Stephen K. Burley, Michael W. Deininger
Journal: Blood
Blood (2007) 110 (11): 535.
https://doi.org/10.1182/blood.V110.11.535.535
Published: 2007
Journal Articles

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

Thomas O’Hare, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Matthew J. Wong, Caitlyn A. Smith, Amie S. Corbin, Sean Buchanan, PhD, Katayoun A. Jessen, PhD, Crystal Tang, Kevin Holme, PhD, Stephen K. Burley, MD, PhD, Michael W.N. Deininger, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1373.
https://doi.org/10.1182/blood.V108.11.1373.1373
Published: 2006
Journal Articles

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

Daniel W. Sherbenou, Matthew J. Wong, Adil Humayun, Laura S. McGreevey, Rui Yang, MD, Michael C. Heinrich, MD, Richard D. Press, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 434.
https://doi.org/10.1182/blood.V106.11.434.434
Published: 2005